Log in to save to my catalogue

Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in pat...

Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in pat...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7035216

Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis

About this item

Full title

Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis

Publisher

Berlin/Heidelberg: Springer Berlin Heidelberg

Journal title

Journal of neurology, 2020-03, Vol.267 (3), p.703-712

Language

English

Formats

Publication information

Publisher

Berlin/Heidelberg: Springer Berlin Heidelberg

More information

Scope and Contents

Contents

Hereditary transthyretin-mediated (hATTR) amyloidosis is a progressive, debilitating disease often resulting in early-onset, life-impacting autonomic dysfunction. The effect of the RNAi therapeutic, patisiran, on autonomic neuropathy manifestations in patients with hATTR amyloidosis with polyneuropathy in the phase III APOLLO study is reported. Pat...

Alternative Titles

Full title

Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7035216

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7035216

Other Identifiers

ISSN

0340-5354

E-ISSN

1432-1459

DOI

10.1007/s00415-019-09602-8

How to access this item